Kodiak Sciences announced that it will present clinical data for three late-stage retinal disease drugs—Zenkuda, tabirafusp-ted, and KSI-101—at the American Academy of Ophthalmology Annual Meeting (AAO 2026). Key highlights include the first scientific presentation of Phase 3 DAYBREAK results for wet age-related macular degeneration, showing non-inferior vision gains compared to aflibercept. Additional data from Phase 3 GLOW2 for diabetic retinopathy and Phase 1b APEX for macular edema secondary to inflammation will also be shared. These presentations mark important milestones as Kodiak advances its portfolio targeting major retinal diseases with potential market impact.
Kodiak Sciences clinical data presentations provide context for health sector activity on Pluang. Of 100 priced US health stocks, 52 rose and 38 fell today. Notable movers include Quest Diagnostics Inc (DGX) at USD 232.36 (+1.71%), Hims and Hers Health Inc (HIMS) at USD 28.99 (-1.63%), and Cronos Group Inc (CRON) at USD 3.33 (+1.37%). Data as of Oct 07, 2026 18:11 WIB.
FICO is cutting about 15% of its workforce, roughly 570 jobs, following a regulatory change that ended its exclusive use on the mortgage pricing grid by Fannie Mae and Freddie Mac. This change allows lenders to use VantageScore alongside FICO, leadin...
DA Davidson increased its price target for Micron from $2,100 to $3,000, reflecting a 42% upside potential based on strong fiscal Q4 results and optimistic fiscal 2027 guidance. The firm highlighted Micron's robust revenue growth, driven by AI-relate...
Camtek Ltd. announced it will host an exclusive Investor & Analyst Breakfast Presentation on October 14, 2026, during SEMICON West in San Francisco. The company's leadership will share updates on its growth strategy, technology roadmap, and financial...
Marvell Technology's stock has surged over 200% in the past year due to booming AI data center demand. A $5,000 investment today could be worth about $6,763 by 2031, reflecting a 35.27% total return with an annualized gain of 6.23%. Key growth driver...
Oracle Cloud Infrastructure (OCI) revenue surged 121% to $7.388 billion, growing three times faster than Amazon Web Services (AWS), which posted $42.232 billion with 37% growth. Despite OCI's rapid expansion and strong GPU usage, AWS maintains a mass...
